Niagen Bioscience, Inc. - Common Stock (NQ:NAGE)

3.450 -0.050 (-1.43%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 7, 2026 Add to My Watchlist

Price and Volume

Volume	818,468
Open	3.530
Bid (Size)	3.430 (200)
Ask (Size)	3.500 (300)
Prev. Close	3.500
Today's Range	3.450 - 3.640
52wk Range	3.175 - 12.65
Shares Outstanding	68,196,526
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Niagen Bioscience to Present at the 16th Annual East Coast IDEAS Investor Conference

June 03, 2026

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science

June 02, 2026

From Niagen Bioscience, Inc

Via Business Wire

Performance

YTD	-44.8%	-44.8%
1 Month	+2.4%	+2.4%
3 Month	-22.8%	-22.8%
6 Month	-49.0%	-49.0%
1 Year	-72.3%	-72.3%

More News

Niagen Bioscience Announces Participation in Upcoming Investor Conferences

May 08, 2026

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience (NASDAQ:NAGE) Shares Slide After Q1 Earnings Miss and Spending Guidance ↗

May 06, 2026

Via Chartmill

Niagen Bioscience Inc (NASDAQ:NAGE) Reports Q4 2025 Revenue Beat and Mixed Earnings ↗

March 04, 2026

Via Chartmill

Niagen (NAGE) Q1 2026 Earnings Call Transcript ↗

May 06, 2026

Via The Motley Fool

Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results

May 06, 2026

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering

May 04, 2026

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus™

April 28, 2026

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026

April 22, 2026

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience Collaborates with USP to Establish First-Ever USP Monograph for Nicotinamide Riboside Chloride (NRCl), the Patented Form in Niagen®

April 09, 2026

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience Announces First Cruise Ship Clinic Partnership with OneSpaWorld, Bringing the NAD-Boosting Benefits of Niagen IV to the High Seas

March 31, 2026

From Niagen Bioscience, Inc

Via Business Wire

Four Stocks at the Intersection of Enzymes, Longevity, and the $400 Billion Wellness Boom (CELV, NAGE, MTEX, CDXS)

March 24, 2026

Via AB Newswire

Niagen Bioscience Increases Share Repurchase Program to $20 Million

March 19, 2026

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience to Present at the 38th Annual ROTH Conference

March 18, 2026

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience Surpasses 300 External Research Agreements from Leading Global Institutions on Niagen®, Contributing to 45 Published Clinical Studies

March 17, 2026

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience (NAGE) Earnings Transcript ↗

March 04, 2026

Via The Motley Fool

Niagen Bioscience Launches Niagen® Skincare Innovation Lab and Debuts Dermatologist-Tested Niagen NanoCloud™, From Tru Niagen Powered by Patented Niagen®

March 10, 2026

From Niagen Bioscience, Inc

Via Business Wire

Get insights into the top gainers and losers of Wednesday's after-hours session. ↗

March 04, 2026

Via Chartmill

Niagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 million, 103% Net Income Increase to $17.4 million or $0.22 Basic EPS in 2025

March 04, 2026

From Niagen Bioscience, Inc

Via Business Wire

Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone

March 03, 2026

Via FinancialNewsMedia

Niagen Bioscience to Streamline and Focus its Operations with the Sale of ChromaDex Reference Standards Business to LGC in All-Cash Transaction

February 26, 2026

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience Secures New U.S. Patent Covering Intravenous and Injection Formulations and Methods of Use for Nicotinamide Riboside (NR), Niagen®

February 25, 2026

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience is the Premiere Sponsor of the Inaugural “NAD for Health: Opportunities & Challenges” Conference Hosted by the University of Copenhagen

February 09, 2026

From Niagen Bioscience, Inc.

Via Business Wire

Niagen Bioscience to Report Fourth Quarter and Full Year 2025 Financial Results on Wednesday, March 4, 2026

February 06, 2026

From Niagen Bioscience, Inc

Via Business Wire

Frequently Asked Questions

Is Niagen Bioscience, Inc. - Common Stock publicly traded?

Yes, Niagen Bioscience, Inc. - Common Stock is publicly traded.

What exchange does Niagen Bioscience, Inc. - Common Stock trade on?

Niagen Bioscience, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Niagen Bioscience, Inc. - Common Stock?

The ticker symbol for Niagen Bioscience, Inc. - Common Stock is NAGE on the Nasdaq Stock Market

What is the current price of Niagen Bioscience, Inc. - Common Stock?

The current price of Niagen Bioscience, Inc. - Common Stock is 3.450

When was Niagen Bioscience, Inc. - Common Stock last traded?

The last trade of Niagen Bioscience, Inc. - Common Stock was at 07/07/26 04:00 PM ET

What is the market capitalization of Niagen Bioscience, Inc. - Common Stock?

The market capitalization of Niagen Bioscience, Inc. - Common Stock is 235.28M

How many shares of Niagen Bioscience, Inc. - Common Stock are outstanding?

Niagen Bioscience, Inc. - Common Stock has 235M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.